From: Benefits and harms of medical cannabis: a scoping review of systematic reviews
Author, year {refid} | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator | Outcomes | Conclusions from data | AMSTAR-2 rating |
---|---|---|---|---|---|---|---|---|
Walsh, 2017 [19] | 1960–Sept 2015; 2 | Government | 31 | Mental health | I: Plant-derived cannabinoids C: Cannabinoid with no THC | • Improvement in anxiety and depression | Only one RCT included (combined with cross-sectional data) | CL |
O’Neil, 2017 [33] | Inception–Mar 2017; 6 | Government | 5 | PTSD | I: All types of cannabinoids C: Different dose or different duration of dose of cannabinoids | N/A observational data | N/A observational data | M |
McLoughlin, 2014 [45] | To Aug 12, 2013; 6 | Non-profit | 1 | Schizophrenia | I: Plant-derived cannabinoids C: Amisulpride | • Mental state outcomes | Only one study included | H |